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Introduction
After the menopause, cardiovascular disease increases
and is the leading cause of death among postmeno-
pausal women [1,2]. Over the last decade, many obser-
vational studies have shown that hormone therapy
(HT) appears to reduce the risks of vascular disease
[3–9]. In 1998, however, the findings of the Heart and
Estrogen/Progestin Replacement Study, the first blinded,
placebo-controlled, randomized clinical trial of HT for
the secondary prevention of cardiac disease in post-
menopausal women, found no overall reduction in risk of
coronary heart disease events among postmenopausal
women [10]. Results of the Women’s Health Initiative
regarding primary prevention of coronary heart disease
showed similar results or even some harm during the
first year using HT consisting of estrogen/progesterone
therapy (EPT) [11]. However, the population in both
clinical trials mainly included patients aged 60–80 years,
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SUMMARY
Objective: This study analyzed whether continuous combined oral estradiol and norethisterone had any effect
on the pulsatility index (PI) of the internal carotid and uterine arteries in Taiwanese early postmenopausal
women.
Materials and Methods: A group of 40 healthy postmenopausal women with no history of hormone therapy
(HT) participated in this study and were randomly subdivided into two groups: HT treatment group (n = 20)
and placebo group (n = 20). PI was evaluated with color Doppler ultrasound at the beginning of the study and
after 4 months of HT (2 mg 17β-estradiol + 1 mg norethisterone acetate) or placebo.
Results: There was no significant change in the PI of the internal carotid and the uterine arteries after 4 months
of HT.
Conclusion: This HT regimen showed no significant negative impact on vascular resistance in Taiwanese early
postmenopausal women. Results are compatible with the updated recommendations on HT stating that there
is little cardiovascular risk when HT is initiated within a few years of the menopause. [Taiwan J Obstet Gynecol
2009;48(1):60–64]
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who were more than 10 years from the beginning of
the menopause, as opposed to younger women receiving
HT in Taiwan.
An increase in vascular resistance, as assessed by
Doppler ultrasound, is related to a higher cardiovas-
cular risk among postmenopausal women. The mech-
anism in which estrogen reduces the pulsatility index
(PI), which is an expression of resistance to flow, was
first observed in the uterine artery [12], then in the
internal carotid artery [13–16]. The effect on periph-
eral vascular resistance might explain the cardiovas-
cular protection attributed to estrogen. In women with
an intact uterus, the concomitant use of progesto-
gen has been suggested to protect the endometrium;
women who receive continuous combined HT have 
a reduced risk of endometrial cancer [17]. Whether
there is a difference in the coronary effects when the
treatment includes adding progestogen rather than just
estrogen alone has not been established. The effects,
however, may be more favorable with the use of estro-
gen alone [18].
The aim of this study was to investigate whether EPT
had beneficial or harmful effects on vascular resistance
in the uterine and internal carotid arteries in early post-
menopausal Taiwanese women.
Materials and Methods
This was a single centre, double-blind, placebo-
controlled, randomized study.
Subjects
A group of 40 healthy postmenopausal women with-
out any previous history of hormone use (aged 47–
52 years; criteria of inclusion and exclusion shown in
Table 1) participated in the study with informed con-
sent. Menopause was diagnosed by natural amenor-
rhea of at least 6 months, follicle-stimulating hormone
(FSH) level > 40 mIU/mL, and estradiol < 20 pg/mL.
Treatments and assessments
First, we evaluated the PI, defined as the ratio of the
difference between maximal systolic velocity and final
diastolic velocity to mean velocity, all obtained in the
same cardiac cycle using color Doppler velocimetry of
the internal carotid and uterine arteries, and obtained
a baseline. Subsequently, the 40 women were random-
ized to either the experimental group (n = 20) or con-
trol group (n = 20). The former received 4 months of
HT (2 mg 17β-estradiol + 1 mg norethisterone acetate),
while the latter received matched placebo tablets. We
re-evaluated the PI after 4 months of therapy.
Color Doppler ultrasound was performed by a well-
trained technologist and supervised by an ultrasound
specialist.
Statistical analysis
The statistical methods used included descriptive sta-
tistics, paired t test and two-sample t test. Treatment
effect comparison between the two study groups em-
ployed the ratio T4/T0 (where T4 = PI at 4 months and
T0 = PI at baseline), thus individual bias was deleted
from the numerator and the denominator of the ratio.
Results
Of the 40 women enrolled, 37 completed the clinical
trial, 20 of which were in the HT group and 17 in 
the placebo group. There was no significant difference
between the groups in terms of age, time of meno-
pause, height, and weight (Table 2). The menopause
had occurred within 2.5 years (mean, 1.5 years).
Baseline PI values for the internal carotid and uterine
arteries were similar between the HT group and the
placebo group (p = 0.32 and p = 0.17 for the internal
carotid artery and uterine artery, respectively), in com-
parison of the mean values (Table 3). Although the
results were insignificant in both groups, there was a
slight increase in the PI value of the internal carotid
artery and a slight decrease in the PI value of the uter-
ine artery from baseline to 4 months in both the HT
and the placebo groups (Figure 1 and Table 3). Table 4
and Figure 2 show T4/T0, where the geometric mean of
Table 1. Criteria of inclusion and exclusion
Inclusion criteria—women who fulfilled all the criteria
below:
1. Spontaneous menopause within 3 years and intact
uterus
2. Follicle-stimulating hormone > 40 mIU/mL
3. Estradiol < 20 pg/mL
4. Menopausal symptoms
Exclusion criteria—women with any one of the below:
1. Hormone-related neoplasm, such as breast cancer
or endometrial cancer
2. Hepatic disease with irreversible liver function
impairment or cancer of liver
3. Thromboembolism or cerebral vessel disease
4. Abnormal uterine bleeding of unknown etiology
5. Uncontrolled hypertension or diabetes mellitus
6. History of prior hormone therapy within 3 months
7. Steroid-taking
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the internal carotid artery PI was 1.13 (HT group) and
1.10 (placebo group), and the geometric mean of the
uterine artery PI was 0.82 (HT group) and 0.77 (placebo
group). Note that the trends from baseline to 4 months
are consistent with the above findings. In addition, from
the t test, the mean of T4/T0 in the HT group was not
significantly larger than in the placebo group in either
the internal carotid artery PI (p = 0.32) or uterine artery
Table 2. Summary of patient demographics
Characteristics Hormone therapy (n = 20) Placebo (n = 17) p
Age (yr) 51.5 ± 3.70 50.5 ± 2.79 0.359
Time since menopause (mo) 17.73 ± 8.38 19.58 ± 7.71 0.769
Body weight (kg) 54.29 ± 5.91 55.88 ± 6.73 0.449
Body height (cm) 151.5 ± 23.45 155 ± 5.40 0.514
Table 3. Internal carotid artery pulsatility index (PI) and uterine artery PI in different treatment groups and time points
Placebo (n = 17) Hormone therapy (n = 20)
PI Baseline 4 months Paired difference Baseline 4 months Paired difference 
(T0−) (T4−) (T0− − T4−)* (T0+) (T4+) (T0+ − T4+)†
Internal carotid artery‡
Mean 1.02 1.13 −0.10 0.96 1.13 –0.16
SD 0.15 0.19 0.15 0.15 0.35 0.36
Uterine artery§
Mean 2.52 2.08 0.44 3.16 2.58 0.57
SD 1.04 1.30 1.39 1.61 1.17 1.85
*Paired t test for H1 : μD > 0, where μD = mean of (T0− − T4−), p = 0.99 (internal carotid artery) and 0.10 (uterine artery); †paired t test for H1 : μD > 0, where
μD = mean of (T0+ − T4+), p = 0.97 (internal carotid artery) and 0.09 (uterine artery); ‡p = 0.32, comparing the mean values of placebo and hormone treatment
groups at baseline; §p = 0.17, comparing the mean values of placebo and hormone treatment groups at baseline. SD = standard deviation.
Table 4. Comparing hormone therapy with placebo at T4/T0 for the internal carotid artery pulsatility index (PI) and uterine
artery PI
T4/T0
Hormone therapy on internal carotid artery PI Hormone therapy on uterine artery PI
+ − p* + − p*
Mean† 1.13 1.10 0.32 0.82 0.77 0.38
95% CI (1.00, 1.29) (1.03, 1.18) (0.63, 1.07) (0.55, 1.07)
*t test H0 : μ− <μ+, in the log transform of the ratio, log(T4/T0), where the analyzed data will be more symmetric and closer to the normal distribution; †geometric
mean, the anti-logarithm of the arithmetic mean of log(T4/T0). T4 = PI at 4 months; T0 = PI at baseline; + = with hormone therapy; − = without hormone therapy;
CI = confidence interval.
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Figure 1. The box plots of pulsatility index from the internal carotid artery and uterine artery, with and without hormone therapy,
and time points (baseline and 4 months). HRT+ = hormone therapy group; HRT− = placebo group.
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PI (p = 0.38), i.e. the extent of increase in the internal
carotid artery and the decrease in the uterine artery in
the HT group was similar to that of the placebo group.
From this study, there is no significant evidence that
HT increases PI in the internal carotid or uterine arteries.
Discussion
In this study, after 4 months of HT (2 mg 17β-estradiol
+ 1 mg norethisterone acetate), no significant changes
were noted regarding the PI values of the uterine and
internal carotid arteries. This implies that, at least for
early postmenopausal Taiwanese women, this regimen
of HT does not have a harmful impact on vascular
resistance. This is compatible with the consensus that
the cardiovascular risks are small when HT is initiated
within a few years of menopause [18].
Estrogen benefits the vascular system, including
improvement of the lipid profile [19], and production
of prostacyclin and nitrogen oxide [20], the latter of
which may cause the vasodilatory effects of estrogen
(i.e. to reduce the PI). Nearly all studies involving the
uterine arteries have demonstrated an important re-
duction in PI after estrogen administration [15,16,21].
However, the administration of a progestin to protect
the endometrium may reduce the positive cardiovas-
cular effects of estradiol. This reduction depends on
the dose and the androgenicity of the progestin [22].
Nevertheless, no consensus has been reached regard-
ing duration of use. In our present study, results after 
4 months of HT showed no significant reduction in PI
on the uterine artery and even a slight increase in the
internal carotid artery. As we know, norethisterone is an
estrane derivative which has relatively high androgenicity.
In past studies, norethisterone partially antagonized the
reduction in the carotid artery PI in postmenopausal
women under estrogen replacement therapy [23]. Recent
reviews demonstrated that the least antagonistic effect on
lipid profile was seen with medrogestone, progesterone
and cyproterone acetate. On the other hand, a marked
antagonistic effect was observed with medroxyproges-
terone acetate, norgestrel and norethindrone [24–30].
In conclusion, not all HT preparations (e.g. EPT)
exert the same effects on the vasculature, and the choice
of progestogen may influence vascular risk at different
levels. In addition, it is possible that a lower dose of
progestogen reduces the vascular benefit of estrogen
to a lesser extent.
In the present study we observed that there is a 
tendency towards a reduction in the uterine artery PI
value and an increase in that of the internal carotid
artery. Similar results were also obtained in a short-
term placebo-controlled trial carried out with 50 post-
menopausal women [31]. The HT group also received
2mg of estradiol plus 1mg of norethisterone acetate and
showed no significant decrease in the internal carotid
artery PI. This might suggest that the increased flow
obtained in the uterine bed cannot be extended to other
organs. That is probably because, by comparison to
other systems, the reproductive system is much more
sensitive to the action of estrogens by having a larger
amount of estrogen receptors. These results may explain
why EPT had no effect in the prevention of coronary
heart disease during the Women’s Health Initiative clin-
ical trial [11]. Further clinical trials are needed to clarify
if other combinations, dosage, duration and routes of
HT are involved in the complex and multiple mechanisms
of cardiovascular action in Taiwanese postmenopausal
women.
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Figure 2. The box plots of pulsatility index (PI) ratio T4/T0, where T4 = PI at 4 months and T0 = PI at baseline, in the internal
carotid and uterine arteries between hormone treatment (treatment 1) and placebo treatment (treatment 0).
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